Baudax Bio (BXRX) Misses Q3 EPS by 5c; Cash and Cash Equivalents of $24.9M

Baudax Bio (NASDAQ: BXRX) reported Q3 EPS of ($0.20), $0.05 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $600 thousand.

For earnings history and earnings-related data on Baudax Bio (BXRX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
• Centene names new CFO as Drew Asher plans to retire